# Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

> **NCT05314998** · PHASE3 · NOT_YET_RECRUITING · sponsor: **John Neoptolemos** · enrollment: 394 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** Folinic acid
- **DRUG:** 5-fluorouracil
- **DRUG:** Gemcitabine
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT05314998
- **Lead sponsor:** John Neoptolemos
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2031-01-01
- **Final completion:** 2031-09-01
- **Target enrollment:** 394 (ESTIMATED)
- **Last updated:** 2024-12-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05314998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05314998, "Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05314998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*